Regeneron-Sanofi’s drug for lung disease gets US approval
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.
HQ Team January 21, 2024: The FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical.
HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.
HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.
The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of.
HQ Team August 30, 2023: Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency. Tecentriq.
HQ Team July 24, 2023: British pharmaceutical firm, GSK Plc., has got marketing authorization from the European Medicines Authority for its injectable, and.
HQ Team June 26, 2023: Pfizer Inc. announced that USFDA has accepted its biologics license application for treating bleeding disorders in adults through.
HQ Team June 21, 2023: The USFDA has approved Pfizer Inc’s oral Talzenna drug in combination with Xtandi to treat advanced prostate cancer.